Calabasas Behavioral Health and BrainsWay Host “After the Smoke Clears”

Free Mental Health Event to Help Los Angeles County Cope with Recent Wildfires and Mass Shooting

Jerusalem, ISRAEL

CALABASAS, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Calabasas Behavioral Health, a leading mental health service provider in Southern California, announced today that it is partnering with BrainsWay, the global leader in the advanced non-invasive treatment of brain disorders, to offer free mental health programs at its joint benefit, After the Smoke Clears, which will take place on Sunday, February 17 at 23622 Calabasas Road, Suite 320, Calabasas, California. In light of the Woolsey Fire and Borderline Bar and Grill mass shooting, the two organizations will be educating the public on coping mechanisms to help people in Calabasas and the neighboring communities recover from the recent tragedies.

“The Los Angeles area has experienced many tragic events in the last few months,” said Dr. Mindy Werner-Crohn, Medical Director of Calabasas Behavioral Health. “The Woolsey Fire was one of Los Angeles’ most destructive wildfires, and the Borderline Bar and Grill mass shooting claimed the lives of 12 California residents. We are eager to help those suffering from these traumatic events by offering programs and assessments during this interactive day, providing a warm and nurturing environment to fill those suffering with hope and inspiration and creating a supportive community.”

After the Smoke Clears will offer programs led by board-certified psychiatrists, therapists and other mental health professionals. During the event, they will be addressing topics that survivors and families of victims from these tragedies have to grapple with. Attendees will receive education on mental health care, as well as learn about treatments available to them, including Deep TMS for the treatment of depression and obsessive-compulsive disorder (OCD).

Registration for the event is open to the public at the link below:

Complimentary food and refreshments will be available throughout the day. Registrants can take advantage of the entire program and attend all sessions being offered during the event. For those interested in specific programs, participants will be given customized schedules upon arrival based on their interests. Workshops and presentations being offered at the event can be found below:

  • Discovering your Resilience: Techniques to Help you Cope Through Tragedy (10:00 a.m.)
  • Cognitive Processing Therapy for Tragic Events (10:00 a.m. and 12:00 p.m.)
  • TMS: An Alternative Treatment to Medications (10:00 a.m., 12:00 p.m. and 2:00 p.m.)
  • Helping Your Family Cope with Tragedy (11:00 a.m. and 1:00 p.m.)
  • Managing Increased Substance Abuse (12:00 p.m.)
  • The Impact of PTSD on Your Brain and Body (12:00 p.m.)
  • Helping Your Kids Cope (1:00 p.m.)
  • Rediscovering Your Identity After Loss (2:00 p.m.)
  • Trauma and an Injured Spirit (3:00 p.m.)
  • Navigating Relationships Through Times of Grief (3:00 p.m.)
  • Education and Life-Changing Information For Those Suffering with Depression, Anxiety, OCD, PTSD, and ADHD

About Calabasas Behavioral Health
Calabasas Behavioral Health is committed to providing the best in behavioral health care for the entire family. They treat children, teens and adults, while also utilizing individual, couples and family therapy. The team strives to offer the best care, using a comprehensive biopsychosocial to diagnosing and treating mental health problems, with highly skilled experts in psychopharmacology and psychotherapy. Calabasas Behavioral Health is one of the few providers of OCD treatment, child psychiatry, ADHD management and sports psychiatry in southern California.

About BrainsWay
BrainsWay Ltd./ BrainsWay USA (TASE: BRIN), is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company’s device has been FDA cleared for the treatment of major depressive disorder (MDD) since 2013 and is now FDA cleared (De-Novo) for the treatment of Obsessive Compulsive Disorder (OCD). The Company's systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders.

Media Contact:
Nechama Feuerstein